Top

Published in:

Open Access 01-12-2014 | Minireview

Molecular determinants of context-dependent progesterone receptor action in breast cancer

Authors: Christy R Hagan, Carol A Lange

Published in: BMC Medicine | Issue 1/2014

Abstract

The ovarian steroid hormone, progesterone, and its nuclear receptor, the progesterone receptor, are implicated in the progression of breast cancer. Clinical trial data on the effects of hormone replacement therapy underscore the importance of understanding how progestins influence breast cancer growth. The progesterone receptor regulation of distinct target genes is mediated by complex interactions between the progesterone receptor and other regulatory factors that determine the context-dependent transcriptional action of the progesterone receptor. These interactions often lead to post-translational modifications to the progesterone receptor that can dramatically alter receptor function, both in the normal mammary gland and in breast cancer. This review highlights the molecular components that regulate progesterone receptor transcriptional action and describes how a better understanding of the complex interactions between the progesterone receptor and other regulatory factors may be critical to enhancing the clinical efficacy of anti-progestins for use in the treatment of breast cancer.

Available only for authorised users

Brisken C: Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer. 2013, 13: 385-396.CrossRefPubMed

Kraus WL, Montano MM, Katzenellenbogen BS: Cloning of the rat progesterone receptor gene 5′-region and identification of two functionally distinct promoters. Mol Endocrinol. 1993, 7: 1603-1616.PubMed

Hill KK, Roemer SC, Churchill ME, Edwards DP: Structural and functional analysis of domains of the progesterone receptor. Mol Cell Endocrinol. 2012, 348: 418-429. 10.1016/j.mce.2011.07.017.CrossRefPubMed

Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P: Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. Embo J. 1990, 9: 1603-1614.PubMedPubMedCentral

Owen GI, Richer JK, Tung L, Takimoto G, Horwitz KB: Progesterone regulates transcription of the p21(WAF1) cyclin-dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem. 1998, 273: 10696-10701. 10.1074/jbc.273.17.10696.CrossRefPubMed

Stoecklin E, Wissler M, Schaetzle D, Pfitzner E, Groner B: Interactions in the transcriptional regulation exerted by Stat5 and by members of the steroid hormone receptor family. J Steroid Biochem Mol Biol. 1999, 69: 195-204. 10.1016/S0960-0760(99)00052-7.CrossRefPubMed

Cicatiello L, Addeo R, Sasso A, Altucci L, Petrizzi VB, Borgo R, Cancemi M, Caporali S, Caristi S, Scafoglio C, et al: Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Mol Cell Biol. 2004, 24: 7260-7274. 10.1128/MCB.24.16.7260-7274.2004.CrossRefPubMedPubMedCentral

Hagan CR, Knutson TP, Lange CA: A common docking domain in progesterone receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cells. Nucleic Acids Res. 2013, 41: 8962-8942.CrossRef

Knutson TP, Daniel AR, Fan D, Silverstein KA, Covington KR, Fuqua SA, Lange CA: Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res. 2012, 14: R95-10.1186/bcr3211.CrossRefPubMedPubMedCentral

10.

McKenna NJ, Lanz RB, O’Malley BW: Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev. 1999, 20: 321-344.PubMed

11.

Daniel AR, Faivre EJ, Lange CA: Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells. Mol Endocrinol. 2007, 21: 2890-2906. 10.1210/me.2007-0248.CrossRefPubMed

12.

Lange CA, Shen T, Horwitz KB: Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci U S A. 2000, 97: 1032-1037. 10.1073/pnas.97.3.1032.CrossRefPubMedPubMedCentral

13.

Weigel NL, Bai W, Zhang Y, Beck CA, Edwards DP, Poletti A: Phosphorylation and progesterone receptor function. J Steroid Biochem Mol Biol. 1995, 53: 509-514. 10.1016/0960-0760(95)00098-K.CrossRefPubMed

14.

Daniel AR, Gaviglio AL, Czaplicki LM, Hillard CJ, Housa D, Lange CA: The progesterone receptor hinge region regulates the kinetics of transcriptional responses through acetylation, phosphorylation, and nuclear retention. Mol Endocrinol. 2011, 24: 2126-2138.CrossRef

15.

Pierson-Mullany LK, Lange CA: Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol Cell Biol. 2004, 24: 10542-10557. 10.1128/MCB.24.24.10542-10557.2004.CrossRefPubMedPubMedCentral

16.

Hagan CR, Regan TM, Dressing GE, Lange CA: CK2-dependent phosphorylation of progesterone receptors (PR) on Ser81 regulates PR-B isoform-specific target gene expression in breast cancer cells CK2. Mol Cell Biol. 2011, 31: 2439-2452. 10.1128/MCB.01246-10.CrossRefPubMedPubMedCentral

17.

Faivre EJ, Daniel AR, Hillard CJ, Lange CA: Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors. Mol Endocrinol. 2008, 22: 823-837. 10.1210/me.2007-0437.CrossRefPubMedPubMedCentral

18.

Ballare C, Uhrig M, Bechtold T, Sancho E, Di Domenico M, Migliaccio A, Auricchio F, Beato M: Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol Cell Biol. 2003, 23: 1994-2008. 10.1128/MCB.23.6.1994-2008.2003.CrossRefPubMedPubMedCentral

19.

Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL, Miller WT, Edwards DP: Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell. 2001, 8: 269-280. 10.1016/S1097-2765(01)00304-5.CrossRefPubMed

20.

Diaz Flaque MC, Vicario R, Proietti CJ, Izzo F, Schillaci R, Elizalde PV: Progestin drives breast cancer growth by inducing p21(CIP1) expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2. Steroids. 2013, 78: 559-567. 10.1016/j.steroids.2012.11.003.CrossRefPubMed

21.

Narayanan R, Adigun AA, Edwards DP, Weigel NL: Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. Mol Cell Biol. 2005, 25: 264-277. 10.1128/MCB.25.1.264-277.2005.CrossRefPubMedPubMedCentral

22.

Beral V: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003, 362: 419-427.CrossRefPubMed

23.

Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, et al: Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010, 304: 1684-1692. 10.1001/jama.2010.1500.CrossRefPubMed

24.

Birrell SN, Butler LM, Harris JM, Buchanan G, Tilley WD: Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer. FASEB J. 2007, 21: 2285-2293. 10.1096/fj.06-7518com.CrossRefPubMed

25.

Courtin A, Communal L, Vilasco M, Cimino D, Mourra N, de Bortoli M, Taverna D, Faussat AM, Chaouat M, Forgez P, et al: Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res Treat. 2012, 131: 49-63. 10.1007/s10549-011-1394-5.CrossRefPubMed

26.

Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F: Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005, 114: 448-454. 10.1002/ijc.20710.CrossRefPubMed

27.

Lyytinen H, Pukkala E, Ylikorkala O: Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol. 2009, 113: 65-73.CrossRefPubMed

28.

Lanari C, Lamb CA, Fabris VT, Helguero LA, Soldati R, Bottino MC, Giulianelli S, Cerliani JP, Wargon V, Molinolo A: The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer. 2009, 16: 333-350. 10.1677/ERC-08-0244.CrossRefPubMed

29.

Lanari C, Molinolo AA: Progesterone receptors-animal models and cell signalling in breast cancer. Diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer. Breast Cancer Res. 2002, 4: 240-243. 10.1186/bcr539.CrossRefPubMedPubMedCentral

30.

Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA: Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci U S A. 2008, 105: 5774-5779. 10.1073/pnas.0706216105.CrossRefPubMedPubMedCentral

31.

Horwitz KB, Sartorius CA: Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab. 2008, 93: 3295-3298. 10.1210/jc.2008-0938.CrossRefPubMedPubMedCentral

32.

Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD, Khokha R: Progesterone induces adult mammary stem cell expansion. Nature. 2010, 465: 803-807. 10.1038/nature09091.CrossRefPubMed

33.

Santen RJ: Risk of breast cancer with progestins: critical assessment of current data. Steroids. 2003, 68: 953-964. 10.1016/S0039-128X(03)00138-7.CrossRefPubMed

34.

Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ: Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab. 1999, 84: 4559-4565.PubMed

35.

Santen RJ: Menopausal hormone therapy and breast cancer. J Steroid Biochem Mol Biol. 2013, 2013: 2013.

36.

Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, Schneider P, Brisken C: Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci U S A. 2010, 107: 2989-2994. 10.1073/pnas.0915148107.CrossRefPubMedPubMedCentral

37.

Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, Eaves CJ, Visvader JE, Lindeman GJ: Steroid hormone receptor status of mouse mammary stem cells. J Natl Cancer Inst. 2006, 98: 1011-1014. 10.1093/jnci/djj267.CrossRefPubMed

38.

Groshong SD, Owen GI, Grimison B, Schauer IE, Todd MC, Langan TA, Sclafani RA, Lange CA, Horwitz KB: Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol. 1997, 11: 1593-1607. 10.1210/mend.11.11.0006.CrossRefPubMed

39.

Clarke RB, Howell A, Anderson E: Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression. Breast Cancer Res Treat. 1997, 45: 121-133. 10.1023/A:1005805831460.CrossRefPubMed

40.

Communal L, Vilasco M, Hugon-Rodin J, Courtin A, Mourra N, Lahlou N, Dumont S, Chaouat M, Forgez P, Gompel A: Ulipristal acetate does not impact human normal breast tissue. Hum Reprod. 2012, 27: 2785-2798. 10.1093/humrep/des221.CrossRefPubMed

41.

Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye JF, Raffoul W, Fiche M, Dougall W, Schneider P, et al: Progesterone/RANKL is a major regulatory axis in the human breast. Sci Transl Med. 2013, 5: 182ra155.CrossRef

42.

Robertson JF, Willsher PC, Winterbottom L, Blamey RW, Thorpe S: Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer. 1999, 35: 214-218. 10.1016/S0959-8049(98)00388-8.CrossRefPubMed

43.

Hagan CR, Daniel AR, Dressing GE, Lange CA: Role of phosphorylation in progesterone receptor signaling and specificity. Mol Cell Endocrinol. 2012, 357: 43-49. 10.1016/j.mce.2011.09.017.CrossRefPubMed

44.

Dressing GE, Hagan CR, Knutson TP, Daniel AR, Lange CA: Progesterone receptors act as sensors for mitogenic protein kinases in breast cancer models. Endocr Relat Cancer. 2009, 16: 351-361. 10.1677/ERC-08-0281.CrossRefPubMedPubMedCentral

45.

46.

Daniel AR, Lange CA: Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells. Proc Natl Acad Sci U S A. 2009, 106: 14287-14292. 10.1073/pnas.0905118106.CrossRefPubMedPubMedCentral

47.

Jozwik KM, Carroll JS: Pioneer factors in hormone-dependent cancers. Nat Rev Cancer. 2012, 12: 381-385. 10.1038/nrc3263.CrossRefPubMed

48.

Magnani L, Eeckhoute J, Lupien M: Pioneer factors: directing transcriptional regulators within the chromatin environment. Trends Genet. 2011, 27: 465-474. 10.1016/j.tig.2011.07.002.CrossRefPubMed

49.

Clarke CL, Graham JD: Non-overlapping progesterone receptor cistromes contribute to cell-specific transcriptional outcomes. PLoS One. 2012, 7: e35859-10.1371/journal.pone.0035859.CrossRefPubMedPubMedCentral

50.

Obr AE, Grimm SL, Bishop KA, Pike JW, Lydon JP, Edwards DP: Progesterone receptor and Stat5 signaling crosstalk through RANKL in mammary epithelial cells. Mol Endocrinol. 2013, 27: 1808-1824. 10.1210/me.2013-1077.CrossRefPubMedPubMedCentral

51.

Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL, et al: Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res. 2009, 69: 6131-6140.CrossRefPubMed

52.

Need EF, Selth LA, Harris TJ, Birrell SN, Tilley WD, Buchanan G: Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor alpha in luminal breast cancer cells. Mol Endocrinol. 2012, 26: 1941-1952. 10.1210/me.2011-1314.CrossRefPubMedPubMedCentral

53.

Giulianelli S, Vaque JP, Soldati R, Wargon V, Vanzulli SI, Martins R, Zeitlin E, Molinolo AA, Helguero LA, Lamb CA, et al: Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters. Cancer Res. 2012, 72: 2416-2427. 10.1158/0008-5472.CAN-11-3290.CrossRefPubMed

54.

Daniel AR, Gaviglio AL, Knutson TP, Ostrander JH, D'Assoro AB, Ravindranathan P, Peng Y, Raj GV, Yee D, Lange CA: Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. Oncogene. 2014, doi:10.1038/onc.2013.579. [Epub ahead of print]

55.

Tawfic S, Yu S, Wang H, Faust R, Davis A, Ahmed K: Protein kinase CK2 signal in neoplasia. Histol Histopathol. 2001, 16: 573-582.PubMed

56.

Guerra B, Issinger OG: Protein kinase CK2 in human diseases. Curr Med Chem. 2008, 15: 1870-1886. 10.2174/092986708785132933.CrossRefPubMed

57.

Meggio F, Pinna LA: One-thousand-and-one substrates of protein kinase CK2?. FASEB J. 2003, 17: 349-368. 10.1096/fj.02-0473rev.CrossRefPubMed

58.

Zhang Y, Beck CA, Poletti A, Edwards DP, Weigel NL: Identification of phosphorylation sites unique to the B form of human progesterone receptor. In vitro phosphorylation by casein kinase II. J Biol Chem. 1994, 269: 31034-31040.PubMed

59.

Castelli M, Camps M, Gillieron C, Leroy D, Arkinstall S, Rommel C, Nichols A: MAP kinase phosphatase 3 (MKP3) interacts with and is phosphorylated by protein kinase CK2alpha. J Biol Chem. 2004, 279: 44731-44739. 10.1074/jbc.M407669200.CrossRefPubMed

60.

Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature. 2012, 490: 61-70. 10.1038/nature11412.CrossRef

61.

Hilton HN, Graham JD, Kantimm S, Santucci N, Cloosterman D, Huschtscha LI, Mote PA, Clarke CL: Progesterone and estrogen receptors segregate into different cell subpopulations in the normal human breast. Mol Cell Endocrinol. 2012, 361: 191-201. 10.1016/j.mce.2012.04.010.CrossRefPubMed

62.

Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O’Connell P, et al: A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res. 2000, 60: 4026-4029.PubMed

63.

Pooley KA, Healey CS, Smith PL, Pharoah PD, Thompson D, Tee L, West J, Jordan C, Easton DF, Ponder BA, et al: Association of the progesterone receptor gene with breast cancer risk: a single-nucleotide polymorphism tagging approach. Cancer Epidemiol Biomarkers Prev. 2006, 15: 675-682. 10.1158/1055-9965.EPI-05-0679.CrossRefPubMed

64.

De Vivo I, Huggins GS, Hankinson SE, Lescault PJ, Boezen M, Colditz GA, Hunter DJ: A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci U S A. 2002, 99: 12263-12268. 10.1073/pnas.192172299.CrossRefPubMedPubMedCentral

65.

Terry KL, De Vivo I, Titus-Ernstoff L, Sluss PM, Cramer DW: Genetic variation in the progesterone receptor gene and ovarian cancer risk. Am J Epidemiol. 2005, 161: 442-451. 10.1093/aje/kwi064.CrossRefPubMedPubMedCentral

66.

Pathiraja TN, Shetty PB, Jelinek J, He R, Hartmaier R, Margossian AL, Hilsenbeck SG, Issa JP, Oesterreich S: Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res. 2011, 17: 4177-4186. 10.1158/1078-0432.CCR-10-2950.CrossRefPubMedPubMedCentral

67.

Romieu G, Maudelonde T, Ulmann A, Pujol H, Grenier J, Cavalie G, Khalaf S, Rochefort H: The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer. 1987, 74: 455-461.PubMed

68.

Klijn JG, de Jong FH, Bakker GH, Lamberts SW, Rodenburg CJ, Alexieva-Figusch J: Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res. 1989, 49: 2851-2856.PubMed

69.

Perrault D, Eisenhauer EA, Pritchard KI, Panasci L, Norris B, Vandenberg T, Fisher B: Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol. 1996, 14: 2709-2712.PubMed

70.

Jonat W, Bachelot T, Ruhstaller T, Kuss I, Reimann U, Robertson JF: Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Ann Oncol. 2013, 24: 2543-2548. 10.1093/annonc/mdt216.CrossRefPubMed

71.

Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY: Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science. 2006, 314: 1467-1470. 10.1126/science.1130471.CrossRefPubMed

72.

Encarnacion CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA, Osborne CK: Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat. 1993, 26: 237-246. 10.1007/BF00665801.CrossRefPubMed

73.

Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M: Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res. 1995, 55: 3331-3338.PubMed

74.

Hayes E, Nicholson RI, Hiscox S: Acquired endocrine resistance in breast cancer: implications for tumour metastasis. Front Biosci (Landmark Ed). 2011, 16: 838-848. 10.2741/3723.CrossRef

75.

Cleator SJ, Ahamed E, Coombes RC, Palmieri C: A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer. 2009, 9: S6-S17.CrossRefPubMed

76.

Pierson-Mullany LK, Skildum A, Faivre E, Lange CA: Cross-talk between growth factor and progesterone receptor signaling pathways: implications for breast cancer cell growth. Breast Dis. 2003, 18: 21-31.CrossRefPubMed

77.

Mote PA, Balleine RL, McGowan EM, Clarke CL: Colocalization of progesterone receptors A and B by dual immunofluorescent histochemistry in human endometrium during the menstrual cycle. J Clin Endocrinol Metab. 1999, 84: 2963-2971.PubMed

78.

Mote PA, Bartow S, Tran N, Clarke CL: Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat. 2002, 72: 163-172. 10.1023/A:1014820500738.CrossRefPubMed

79.

Mote PA, Graham JD, Clarke CL: Progesterone receptor isoforms in normal and malignant breast. Ernst Schering Found Symp Proc. 2007, 1: 77-107.PubMed

80.

Graham JD, Yeates C, Balleine RL, Harvey SS, Milliken JS, Bilous AM, Clarke CL: Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res. 1995, 55: 5063-5068.PubMed

81.

Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP: The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol. 2007, 21: 359-375. 10.1210/me.2006-0337.CrossRefPubMed

82.

Clemm DL, Sherman L, Boonyaratanakornkit V, Schrader WT, Weigel NL, Edwards DP: Differential hormone-dependent phosphorylation of progesterone receptor A and B forms revealed by a phosphoserine site-specific monoclonal antibody. Mol Endocrinol. 2000, 14: 52-65. 10.1210/mend.14.1.0413.CrossRefPubMed

83.

Qiu M, Lange CA: MAP kinases couple multiple functions of human progesterone receptors: degradation, transcriptional synergy, and nuclear association. J Steroid Biochem Mol Biol. 2003, 85: 147-157. 10.1016/S0960-0760(03)00221-8.CrossRefPubMed

84.

Qiu M, Olsen A, Faivre E, Horwitz KB, Lange CA: Mitogen-activated protein kinase regulates nuclear association of human progesterone receptors. Mol Endocrinol. 2003, 17: 628-642. 10.1210/me.2002-0378.CrossRefPubMed

85.

Faivre EJ, Lange CA: Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol Cell Biol. 2007, 27: 466-480. 10.1128/MCB.01539-06.CrossRefPubMed

86.

Lanari C, Wargon V, Rojas P, Molinolo AA: Antiprogestins in breast cancer treatment: are we ready?. Endocr Relat Cancer. 2012, 19: R35-R50. 10.1530/ERC-11-0378.CrossRefPubMed

Title: Molecular determinants of context-dependent progesterone receptor action in breast cancer
Authors: Christy R Hagan
Carol A Lange
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: BMC Medicine / Issue 1/2014
Electronic ISSN: 1741-7015
DOI: https://doi.org/10.1186/1741-7015-12-32

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Molecular determinants of context-dependent progesterone receptor action in breast cancer

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Managing the changing burden of cancer in Asia

Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis

Impact of early daycare on healthcare resource use related to upper respiratory tract infections during childhood: prospective WHISTLER cohort study

Obesity in pregnancy: could lifestyle interventions work?

Sex dependent risk factors for mortality after myocardial infarction: individual patient data meta-analysis

Weight loss required by the severely obese to achieve clinically important differences in health-related quality of life: two-year prospective cohort study